Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thermo Fisher ScientificBSP:TMOS34 -1.22%77 Cash-to-Debt is 0.10 as of Jun. 2026, which is 17% below its 10-year median of 0.12. GuruFocus rates BSP:TMOS34 with a GF Score™ of 77/100 and a GF Value™ of R$63.72 (Fairly Valued). The stock has 10 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks worse than 87.08% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Thermo Fisher Scientific's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.10.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Thermo Fisher Scientificcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Thermo Fisher Scientific's Cash-to-Debt or its related term are showing as below:
BSP:TMOS34'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.12 Max: 0.55
Current: 0.1
During the past 13 years, Thermo Fisher Scientific's highest Cash to Debt Ratio was 0.55. The lowest was 0.03. And the median was 0.12.
BSP:TMOS34's Cash-to-Debt is ranked worse than 87.08% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.07
vs BSP:TMOS34: 0.10
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thermo Fisher Scientific Cash-to-Debt Related Terms
Thermo Fisher Scientific Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BSP:TMOS34 vs DHR, IDXX, A: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (BSP:TMOS34) has a Cash-to-Debt of 0.10 as of Jun. 2026. This is 17% below median its historical median of 0.12. Over the past decade, Thermo Fisher Scientific's Cash-to-Debt has ranged from 0.03 to 0.55. According to the industry distribution chart, Thermo Fisher Scientific ranks #182 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 87.1%.
Is Thermo Fisher Scientific's Cash-to-Debt too high?
Thermo Fisher Scientific's current Cash-to-Debt of 0.10 is 17% below median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.55. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.07. Thermo Fisher Scientific's value of 0.10 is 90.7% below this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #182 out of 209 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Thermo Fisher Scientific has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Cash-to-Debt compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #182 out of 209 companies for Cash-to-Debt. This places Thermo Fisher Scientific in the lower half of its industry. The industry median Cash-to-Debt is 1.07. Thermo Fisher Scientific's value of 0.10 is 90.7% below this benchmark. Historically, Thermo Fisher Scientific's own Cash-to-Debt has ranged from 0.03 to 0.55 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 1.07, Thermo Fisher Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.07, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Cash-to-Debt of 0.10 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Cash-to-Debt is 0.10, which is 17% below median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$63.72, compared to a current price of R$67.20 — trading 5.5% above its estimated fair value. The current Cash-to-Debt is 0.10, which is 17% below median its 10-year median of 0.12 and 90.7% below the Medical Diagnostics & Research industry median of 1.07. Thermo Fisher Scientific's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Cash-to-Debt is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be overvalued.
The current stock price of R$67.20 is trading 5.5% above its estimated GF Value™ of R$63.72.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
Cash-to-Debt: 0.10 (17% below median its 10-year median of 0.12)
GF Value™: R$63.72 vs. price of R$67.20 (5.5% above fair value)
Industry Position: 90.7% below the Medical Diagnostics & Research median (#182 of 209)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
77GF Score
Get the complete analysis for BSP:TMOS34
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
